News
Moderna’s New Flu Shot Shows Strong Results in Older Adults
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA. Copyright © 2025 HealthDay. All rights reserved.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
Investor's Business Daily on MSN1d
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback